Maharashtra hospitals halt paracetamol distribution after quality test failure

Quality control tests conducted by the Maharashtra Food and Drug Administration (FDA) in Nagpur have identified batches of paracetamol 500 mg and telmisartan 40 mg as failing to meet prescribed standards. The findings have prompted immediate action from state health authorities to prevent distribution of the affected medications to patients.

Following the FDA's report, government hospitals across Maharashtra have suspended the supply of these drug batches and initiated the process of recalling existing stocks from their inventories. The move aims to ensure that only quality-assured medicines reach patients through public healthcare facilities.

Paracetamol, a widely used analgesic and antipyretic, and telmisartan, an antihypertensive medication, are commonly prescribed drugs in India. The quality failures identified by regulatory authorities underscore ongoing concerns about pharmaceutical manufacturing standards in the country.

The incident highlights the importance of regular quality audits and batch testing by drug regulatory bodies. The FDA's action reflects efforts to strengthen quality assurance mechanisms within the pharmaceutical supply chain serving India's healthcare system.